Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial. - Hu J; Babiker AG; Reilly CS; Baker JV; Siegel LK (Contemporary clinical trials communications, 2025)